Document Detail


Costs and risks in the management of patients with gastric acid hypersecretion.
MedLine Citation:
PMID:  19581810     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
GOALS: To define both risks and costs of optimal care of patients with gastric acid hypersecretion. BACKGROUND: The management of Zollinger-Ellison syndrome and other gastric acid hypersecretory disorders remains challenging. The optimal strategy for follow-up including gastric acid analysis, laboratory studies, and endoscopy is unknown but important given the potential complications from uncontrolled acid secretion. STUDY: Over the last 18 years, patients with gastric acid hypersecretory disorders have been followed prospectively with gastric acid analysis and endoscopy titrating oral lansoprazole and evaluating for complications. Protocol driven charges were calculated using the most recent information available. RESULTS: After 1 year of treatment optimization, 19 of 67 patients had 43 relapses, (once only in 10 patients). Risk markers for relapse included: (1) antrectomy, 67% relapsed versus 21% in unoperated patients; (2) basal acid output >5 mmol/h (risk=5.17); and (3) poor compliance. On treatment, 79% of 58 intact patients (excluding antrectomy) were lesion-free; 11% had only 1 relapse. Thus 90% were well managed with optimized lansoprazole alone. Protocol driven charges exceeded $25,000 the first year and $7000 annually thereafter. CONCLUSIONS: Relapse is infrequent and generally mild with acid secreting status closely monitored. The ideal strategy to balance costs and testing awaits further study.
Authors:
Basil I Hirschowitz; Naomi Fineberg; C Mel Wilcox; Jean Mohnen; Julie Worthington
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  44     ISSN:  1539-2031     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-22     Completed Date:  2010-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  28-33     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00204373
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / economics,  therapeutic use*
Adult
Anti-Ulcer Agents / economics,  therapeutic use*
Costs and Cost Analysis
Endoscopy, Gastrointestinal / methods
Female
Follow-Up Studies
Gastric Acid / secretion*
Gastric Acidity Determination
Humans
Male
Middle Aged
Prospective Studies
Recurrence
Young Adult
Zollinger-Ellison Syndrome / economics,  physiopathology,  therapy*
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prosp...
Next Document:  Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Ma...